AbbVie vs Merck & Co
AbbVie (ABBV), health care, and Merck & Co (MRK), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
AbbVie is worth $518.9B on the stock market and Merck & Co $355.1B: AbbVie is valued at 46% more. AbbVie trades at 50.5 times earnings and Merck & Co at 145. Over the past year AbbVie's share price has moved +25.9% and Merck & Co's +49.8%.
Key facts
- AbbVie market value
- $518.9B
- Merck & Co market value
- $355.1B
- AbbVie P/E
- 50.5
- Merck & Co P/E
- 145
- AbbVie revenue
- $61.2BFY to 2025-12-31
- Merck & Co revenue
- $65BFY to 2025-12-31
- Superinvestors holding both
- 10
Market values as of .
| Measure | AbbVie | Merck & Co |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $518.9Bhigher | $355.1Blower |
| Revenue | $61.2Blower | $65Bhigher |
| Earnings | $4.2Blower | $18.3Bhigher |
| Employees | 57,000lower | 73,000higher |
| Total assets | $134Blower | $136.9Bhigher |
| Valuation | ||
| P/E | 50.5lower | 145higher |
| P/S | 8.5higher | 5.5lower |
| P/B | — | 7.9 |
| Dividend yield | 2.35%higher | 2.33%lower |
| Profitability | ||
| Operating margin | 24.6% | — |
| Balance sheet | ||
| Net assets | -$3.3Blower | $52.6Bhigher |
| Total liabilities | $137.2Bhigher | $84.2Blower |
| Total debt | $67.5Bhigher | $49.3Blower |
| Cash on hand | $5.2Blower | $14.6Bhigher |
| Price change | ||
| Today | -0.33%lower | -0.29%higher |
| 1 year | +25.9%lower | +49.8%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (10)
- Ken Fisher0.8% / 1.7%
- Ken Griffin0.5% / 0.1%
- David Shaw (founder)0.3% / 0.2%
- Cliff Asness0.2% / 0.4%
- Mairs & Power team0.1% / 0.1%
- Murray Stahl0.1% / 0.1%
- Thomas Russo<0.1% / <0.1%
- Howard Gleicher<0.1% / 2.0%
- Rajiv Jain<0.1% / <0.1%
- Bill Nygren<0.1% / 2.1%
AbbVie only (5)
- Fred DiSanto1.5%
- Larry Robbins0.7%
- Israel Englander0.3%
- Lew Sanders0.1%
- Jensen team0.1%
Merck & Co only (13)
- Bill Smead7.1%
- Thomas Kahn4.9%
- Jeremy Grantham (co-founder)1.6%
- Charles Brandes (founder)1.5%
- Josef Lakonishok1.4%
- Prem Watsa0.9%
- Christopher Bloomstran0.6%
- Sarah Ketterer0.6%
- Mark Boyar0.5%
- Temasek0.3%
- Brandon Haley0.2%
- Joel Greenblatt0.2%
- Dodge & Cox team<0.1%
Percentages are each holding's share of that investor's reported portfolio (under "Both": AbbVie / Merck & Co). Who owns ABBV · Who owns MRK
More on AbbVie
Further comparisons
AbbVie against its closest peers
Merck & Co against its closest peers
Learn
Questions and answers
Which is bigger, AbbVie or Merck & Co?
By market value, AbbVie is the larger: $518.9B against $355.1B for Merck & Co. By revenue in its latest fiscal year, Merck & Co is the larger: $65B against $61.2B for AbbVie.
Which has the higher P/E ratio?
Merck & Co: 145, against 50.5 for AbbVie. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher dividend yield?
AbbVie: 2.35%, against 2.33% for Merck & Co. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which has more debt?
AbbVie: $67.5B, against $49.3B for Merck & Co. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both AbbVie and Merck & Co?
In their latest 13F filings, Ken Fisher, Ken Griffin, David Shaw (founder), Cliff Asness, Mairs & Power team, Murray Stahl, Thomas Russo, Howard Gleicher, Rajiv Jain and Bill Nygren hold both.
Cite this page
Funkfolio, “AbbVie vs Merck & Co”, data as of 17 November 2026. https://funkfolio.com/compare/abbv-vs-mrk
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.